IDEX CORP /DE/
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
IDEX Corporation (IEX) amended its credit agreement, extending its debt maturity to 2031 with a $800 million revolving facility. The new agreement, led by Bank of America, provides financial flexibility for working capital and general corporate purposes. The company's GF Value is estimated at $226.10, with a GF Score of 94/100.
IDEX (IEX) reported strong Q2 earnings, record orders over $1B, and a 42.07% total shareholder return over the past year. Analysts' consensus price target is $254.50, with some valuing it higher at $280.0 and others lower at $215.0. Investors should monitor tariff pressures and sector demand.
IDEX CORP /DE/ (IEX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 13, 2026, L. Paris Watts-Stanfield resigned from the Board of Directors (the “Board”) of IDEX Corporation (the
Over the past 7 days, alphai's AI scored 1 news story mentioning IEX (IDEX CORP /DE/). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent IEX coverage spans earnings, corporate actions and financial news.
In the last 30 days, IEX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($92K). The most active reporter was Anderson Lisa M, SVP, GC, CAO & Corp Sec, with 1 filing.
The new financing improves liquidity and may support future acquisitions or capital projects.
Positive earnings surprise and large order book may push price toward fair‑value levels.
Board composition change is typically low-to-moderate signal value unless tied to strategy, disputes, or committee leadership changes, which are not detailed here.
Raised 2026 guidance plus record orders and margin expansion suggest improving demand visibility, with tariff-related items and segment mix as key swing factors.
Strong quarter with the highest guidance raise in the group supports a constructive bias.
alphai scores every news story that mentions IEX with an AI model for sentiment and relevance, and aggregates insider trades from IDEX CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IDEX Corporation (IEX) amended its credit agreement, extending its debt maturity to 2031 with a $800 million revolving facility. The new agreement, led by Bank of America, provides financial flexibility for working capital and general corporate purposes. The company's GF Value is estimated at $226.10, with a GF Score of 94/100.
2 min readIDEX (IEX) reported strong Q2 earnings, record orders over $1B, and a 42.07% total shareholder return over the past year. Analysts' consensus price target is $254.50, with some valuing it higher at $280.0 and others lower at $215.0. Investors should monitor tariff pressures and sector demand.
2 min readIDEX CORP /DE/ (IEX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 13, 2026, L. Paris Watts-Stanfield resigned from the Board of Directors (the “Board”) of IDEX Corporation (the
2 min readIDEX (IEX) reported Q2 2026 net sales of $920.6 million, up 6% reported and 5% organic. Adjusted diluted EPS rose 12% to $2.32. Orders were $1,071.6 million, a record, up 29% reported and 28% organic. Full-year 2026 guidance was raised: organic growth 5% to 6% and EPS $8.70 to $8.85.
6 min readThe article compares Q2 results for industrial fluid-handling firms. Graco (GGG) reported $590.6M revenue, up 3.3% YoY, but 3% below analyst expectations. Flowserve (FLS) posted $1.17B revenue, down 1.6% YoY, beating forecasts by 0.9%, with mixed guidance. IDEX (IEX) had $920.6M revenue, up 6.4% YoY, beating by 1.7%.
4 min read24/7 Wall St. lists Wednesday analyst research calls. Upgrades include Hilton (HLT) to Buy with a $365 target, Intuitive Surgical (ISRG) to Outperform with a $500 target, Merck (MRK) to Outperform with a $143 target, and Okta (OKTA) to Outperform with a $170 target. Downgrades include The Gap (GAP) to Hold, and Novo Nordisk (NVO) to Hold. Initiations cover Genmab (GMAB) and Marriott (MAR).
6 min readIndian Energy Exchange (IEX) shares fell up to 4% after India’s Supreme Court declined to intervene in a dispute over “market coupling” regulations, letting CERC proceed with drafting. The court said it was not the right stage and made no ruling on merits, leaving IEX free to challenge once notified. IEX closed 3.21% lower at Rs 128.
3 min readIDEX (IEX) Q2 2026 earnings call reported organic revenue growth of 5% and organic orders up 28%. HST led with 47% organic order growth and 12% organic revenue growth. Adjusted EPS was $2.32, above guidance $2.07 to $2.12, and adjusted EBITDA margin rose 70 bps. Free cash flow was $177M, liquidity over $1.1B, and $77M share repurchases. IEEPA tariff refunds added a $0.08 EPS benefit.
9 min readIndian Energy Exchange (IEX) reported July 2026 electricity traded volume of 13,527 MUs, up 7.7% year on year. Day-Ahead market average clearing price rose 19.3% to Rs 4.99/unit, and Real-Time to Rs 4.41/unit, up 15.1%. REC trading fell 56.3% to 7.11 lakh, with clearing prices around Rs 380/REC and Rs 376/REC.
2 min readIDEX (IEX) reported Q2 CY2026 revenue of $920.6M vs $905.4M estimates and adjusted EPS of $2.32 vs $2.11, with adjusted EBITDA $258.3M. CEO Eric Ashleman cited 28% organic order growth and strong Health & Science Technologies demand. Guidance: Q3 revenue $931.4M midpoint and full-year adjusted EPS $8.77 midpoint.
6 min read
